Table 1 Patient characteristics
Patient Nr. | Sex | Age | Disease duration [years] | Pretreatment | EDSS | Stable disease course |
|---|---|---|---|---|---|---|
1 | F | 23 | 3 | Interferon-beta | 1.5 | Yes |
2 | F | 54 | 9 | None | 2 | Yes |
3 | M | 28 | 4 | Interferon-beta | 1.5 | Yes |
4 | M | 33 | 14 | Natalizumab | 4 | Yes |
5 | F | 42 | 14 | Glatiramer acetate | 3 | Yes |
6 | F | 53 | 16 | Interferon-beta | 3.5 | Yes |
7 | F | 47 | 3 | Interferon-beta | 3 | Yes |
8 | F | 47 | 7 | Interferon-beta | 2 | Yes |
9 | F | 41 | 11 | Interferon-beta | 6 | Yes |
10 | F | 46 | 15 | Natalizumab | 4 | Yes |
11 | F | 42 | 2 | None | 1 | Yes |
12 | F | 19 | 2 | None | 1.5 | Yes |
13 | F | 30 | 11 | Natalizumab | 2 | Yes |
14 | M | 35 | 3 | Glatiramer acetate | 2 | Yes |
15 | M | 27 | 3 | Glatiramer acetate | 2 | Yes |
16 | F | 44 | 4 | Interferon-beta | 2.5 | Yes |
17 | F | 27 | 11 | Natalizumab | 2 | No |
18 | F | 29 | 15 | Natalizumab | 6 | Yes |
19 | F | 24 | 11 | None | 1 | Yes |
20 | F | 47 | 6 | Glatiramer acetate | 3 | Yes |
21 | F | 45 | 11 | Glatiramer acetate | 1.5 | Yes |
22 | M | 42 | 3 | Glatiramer acetate | 4 | Yes |
23 | F | 44 | 10 | Interferon-beta | 1.5 | Yes |
24 | M | 38 | 3 | Glatiramer acetate | 1.5 | Yes |
25 | M | 26 | 4 | Interferon-beta | 1.5 | No |
26 | F | 42 | 4 | Glatiramer acetate | 2 | Yes |
27 | M | 29 | 2 | Glatiramer acetate | 2 | Yes |
28 | F | 35 | 2 | Glatiramer acetate | 3 | Yes |
29 | M | 41 | 1 | None | 2 | Yes |
30 | M | 30 | 6 | Interferon-beta | 1.5 | Yes |
31 | M | 28 | 1 | None | 1.5 | Yes |
32 | M | 44 | 10 | Interferon-beta | 4 | Yes |
33 | F | 45 | 10 | Interferon-beta | 4 | Yes |
34 | M | 41 | 19 | Natalizumab | 3 | Yes |
35 | F | 33 | 8 | Glatiramer acetate | 2.5 | Yes |